Having worked in the British, French and Swiss financial press, Romain is able to report on local and international issues, as comfortable in French as in the language of Shakespeare, Romain Fournier leads the editorial team at Marketscreener. Fine connoisseur of the English-speaking markets, Romain delivers an editorial every day on US and UK markets.
RBC is interested in the rising stars of alternative energies such as ITM Power, while also upgrading Anglo American from Outperform to Sector Perform. JPMorgan significantly raises Biogen's price target, thanks to the company's new treatment against Alzheimer.
Anglo American: RBC upgrades from Outperform to Sector Perform with a target of GBp3,400.
AstraZeneca: Berenberg advises its customers to buy the stock. The target price is still set at GBp 95.
Auto Trader: Berenberg remains Hold with a price target raised from GBp 520 to GBp 650.
Biogen : JPMorgan adjusts pt to $435 from $269, maintains neutral rating
GlaxoSmithKline: Berenberg is positive on the stock with a Buy rating. The target price is still set at GBp 1570.